+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Migraine in the United States: Understanding the Migraine Patient Experience

  • Report

  • 141 Pages
  • January 2024
  • Region: United States
  • Health Union
  • ID: 5944066

Unveiling Insights into Migraine Patients' Demographics, Quality of Life Impact, Information-Seeking Behaviors, HCP Engagement, and Treatment Experiences

This Migraine in America report provides a comprehensive look at life for those living with migraine. Using detailed quantitative data, it gives a full picture of the migraine patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.

In the United States, roughly 39 million people have migraine disease.

Migraine in America 2023: Understanding the Migraine Patient Experience offers an in-depth look at the migraine patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the migraine patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more.

What makes this report unique?

Very simply: the focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.

Valuable insights. Informed decisions.

This report lifts the curtain on life with migraine, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs.

This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information.

The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including Migraine.com - to provide information, connection, and support to patients and caregivers in the U.S.

This report includes a deep-dive into:

  • Migraine patient demographics
    • Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions
  • Impact of migraine on quality of life
    • Time since diagnosis, severity, triggers, impact on quality of life, symptoms experienced, and what patients wish others better understood
  • Information-seeking behaviors
    • Information sources used, plus topics of interest
  • HCP engagement
    • Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used
  • Migraine treatment awareness and experiences
    • Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials

Key questions answered in this report:

  • To what extent do people say migraine impacts their overall quality of life?
  • What’s the average number of migraine days per month?
  • What do patients wish others understood about migraine?
  • What percentage of patients see a specialist for migraine treatment?
  • What treatments have the highest aided brand awareness among patients?
  • What percentage of patients use preventive medications?
  • How many patients feel their migraine is well-controlled on their current treatment plan?
  • What percentage of patients are likely to switch or add new treatments in the next six months?
  • What medications have patients discussed with their HCP?
  • What are the top online resources people with migraine use to find information?
  • What kinds of content and information do patients search for?
  • What percentage of patients search for information on treatment options?

Methodology

Migraine in America 2023: Understanding the Migraine Patient Experience consists of:

  • A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions
  • Qualitative patient insights from open-ended responses

Additional details:

  • Fielded: January 16, 2023 to April 14, 2023
  • Convenience sample of 4,416 respondents diagnosed with migraine
  • Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners

Table of Contents

Methodology

Respondent Demographics

Research Highlights

  • Condition Status and Quality of Life
  • Number of Migraine Days Per Month and Triggers
  • Symptoms Experienced
  • Impact on Quality of Life
  • Qualitative Patient Insights

Information-Seeking Behaviors

  • Resources Used to Manage Health
  • Types of Content/Information Sought

Treatment Awareness and Experiences

  • Primary HCP Seen for Migraine Care
  • Aided Brand Awareness of Treatments
  • Acute Prescription Treatment Usage
  • Preventive Treatment Usage
  • Condition Control on Current Treatment and Clinical Trial Interest
  • Treatment Discussions with HCP

Appendix with All Data Charts and Distributions

Products Mentioned

Brands and treatments mentioned in this report include:

  • Oral triptan tablets or fastmelts (such as IMITREX®, MAXALT®, ZOMIG®, sumatriptan)
  • Nasal triptan spray or nasal powder (such as IMITREX®, ONZETRA™ Xsail™, Tosymra®, ZOMIG®)
  • Injection or needleless triptan injection (such as IMITREX®, ZEMBRACE™ SymTouch™)
  • Cambia® (diclofenac potassium)
  • Elyxyb™ (celecoxib) oral solution
  • FIORICET®, FIORINAL® (aspirin, butalbital, and caffeine)
  • MIGRANAL® (dihydroergotamine mesylate)
  • NURTEC® ODT (rimegepant) (used on as-needed basis to treat migraine symptoms)
  • REYVOW™ (lasmiditan)
  • TRUDHESA™ (dihydroergotamine mesylate)
  • UBRELVY™ (ubrogepant)
  • Ergot derivative other than MIGRANAL® or TRUDHESA™, such as DHE-45® (dihydroergotamine), Cafergot® (ergotamine tartrate and caffeine), Ergomar® (ergotamine tartrate tablets)
  • Anti-nausea medications, such as Zofran® (ondansetron), Compazine® (prochlorperazine), Phenergan® (promethazine)
  • Prescription analgesics (""painkillers""), such as Vicodin® (acetaminophen and hydrocodone), OxyContin® (oxycodone), Percocet® (acetaminophen and oxycodone), Dilaudid® (hydromorphone)
  • Prescription muscle relaxants, such as Robaxin® (methocarbamol), Valium® (diazepam), Flexeril® (cyclobenzaprine), ZANAFLEX® (tizanidine)
  • Prescription NSAIDs, such as Aleve® (naproxen), TORADOL® (ketorolac)
  • Cefaly® ACUTE device for acute treatment of migraine attacks
  • Nerivio® device (electronic device for acute treatment of migraine)
  • gammaCore® (non-invasive vagus nerve stimulation device)
  • AIMOVIG® (erenumab)
  • AJOVY® (fremanezumab)
  • BOTOX® (onabotulinumtoxinA) for Chronic Migraine
  • EMGALITY® (galcanezumab)
  • NURTEC® ODT (rimegepant) (taken every other day to prevent migraines or taken in advance of potential migraine triggers)
  • QULIPTA™ (atogepant)
  • Topiramate/Topiramate XR (TOPAMAX®, TROKENDI XR®, generic topiramate)
  • VYEPTI™ (eptinezumab)
  • Antiepileptic drugs other than topiramate, such as Neurontin® (gabapentin)
  • Beta blockers, such as Inderal® (propranolol), TENORMIN® (atenolol), Blocadren® (timolol)
  • Calcium channel blockers, such as CALAN® (verapamil), NORVASC® (amlodipine), flunarizine
  • Antidepressants, such as Cymbalta® (duloxetine), Elavil® (amitriptyline), Effexor® (venlafaxine)
  • Serotonergic agents, such as Sandomigran® (pizotifen), methysergide
  • Oral steroids, such as oral Solu-Medrol®, prednisone, dexamethasone
  • Lidocaine nasal drops
  • Nerve blockers or pain-blocking treatments (such as an occipital nerve block, SpringTMS®, transcranial magnetic stimulation)
  • Cefaly® PREVENT or DUAL device for migraine prevention